Senna Dosing: One Tablet Twice Daily
Start with one tablet (8.6 mg) once daily, not twice daily, and titrate upward based on response. The 2023 AGA-ACG guidelines recommend an initial dose of 8.6-17.2 mg daily for chronic constipation, with a maximum of 4 tablets twice daily (approximately 34.4 mg BID) 1.
Initial Dosing Strategy
- Begin with 8.6-17.2 mg once daily (1-2 tablets at bedtime)
- Taking one tablet BID (twice daily) is acceptable but not the recommended starting point
- The FDA label supports dosing up to 15 mL (approximately 26.4 mg) twice daily as the maximum for adults 2
Titration Approach
Dose adjustment should be guided by symptom response and side effects:
- If inadequate response after 3-5 days: increase to 2 tablets once daily (17.2 mg)
- If still inadequate: can split dosing to BID (one tablet twice daily = 17.2 mg total)
- Further increases: up to 4 tablets BID maximum (approximately 34.4 mg BID) 1
Important caveat: In the only high-quality RCT, 83% of patients reduced their dose from the initial 1 gram daily (significantly higher than typical clinical dosing), suggesting that starting high often leads to intolerable side effects 1.
Evidence Quality and Nuances
The guideline evidence is robust but limited:
- Only one small RCT (n=60) from Japan supports senna's efficacy 3
- That study used 1 gram daily (much higher than standard practice)
- Senna demonstrated significant improvements in spontaneous bowel movements (MD 7.6 per week) and quality of life compared to placebo 1
- Long-term safety and efficacy data are unknown 1
Common Pitfalls to Avoid
- Starting too high: Beginning with BID dosing increases risk of cramping, diarrhea, and dose reduction
- Nighttime accidents: Higher doses combined with overnight stool retention can cause perineal blistering (2.2% incidence in one pediatric series, primarily with doses >60 mg/day) 4
- Tolerance concerns: Recent evidence shows no tolerance development with long-term use when weight-adjusted dosing is maintained 5
Clinical Context
Senna is recommended for:
- Short-term use or rescue therapy primarily 1
- Cost-effective first-line option (<$50/month) 1
- Patients who don't respond adequately to fiber or osmotic laxatives
Consider alternatives if:
- Cramping or abdominal discomfort is limiting
- Long-term daily use is anticipated (consider osmotic agents like PEG which have better long-term safety data)
- Patient has concerns about stimulant laxative dependence (though evidence doesn't support this) 5, 4
Bottom line: One tablet BID is within acceptable dosing but not optimal for initiation. Start with once-daily dosing and escalate only if needed based on response over several days.